Millions of people suffer from pressure wounds, also known as bed sores. It is reported that the rate of pressure ulcers in hospital settings is very prevalent in European and Canadian hospitals ranging form 8% to 26%. In 2013, there were 29,000 documented deaths from pressure ulcers globally, up from 14,000 deaths in 1990. Each year, more than 2.5 million people in the United States develop pressure ulcers and if these wounds develop in a nursing home setting, litigation often ensues for suspected "patient neglect" in these facilities. As a potent wound healing agent, it would be expected that Zhittya's FGf-1 drug would have great potential to accelerate the healing of this class of wounds.